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Abstract
Background: Nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in NAD+ biosynthesis
from nicotinamide, is one of the major factors regulating cancer cells metabolism and is considered a promising
target for treating cancer. The prototypical NAMPT inhibitor FK866 effectively lowers NAD+ levels in cancer cells,
reducing the activity of NAD+-dependent enzymes, lowering intracellular ATP, and promoting cell death.
Results: We show that FK866 induces a translational arrest in leukemia cells through inhibition of MTOR/4EBP1
signaling and of the initiation factors EIF4E and EIF2A. Specifically, treatment with FK866 is shown to induce
5′AMP-activated protein kinase (AMPK) activation, which, together with EIF2A phosphorylation, is responsible for the
inhibition of protein synthesis. Notably, such an effect was also observed in patients’ derived primary leukemia cells
including T-cell Acute Lymphoblastic Leukemia. Jurkat cells in which AMPK or LKB1 expression was silenced or in
which a non-phosphorylatable EIF2A mutant was ectopically expressed showed enhanced sensitivity to the NAMPT
inhibitor, confirming a key role for the LKB1-AMPK-EIF2A axis in cell fate determination in response to energetic
stress via NAD+ depletion.
Conclusions: We identified EIF2A phosphorylation as a novel early molecular event occurring in response to
NAMPT inhibition and mediating protein synthesis arrest. In addition, our data suggest that tumors exhibiting an
impaired LBK1- AMPK- EIF2A response may be especially susceptible to NAMPT inhibitors and thus become an
elective indication for this type of agents.
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Background
Aberrant activation of metabolic pathways has emerged as
an hallmark of proliferating cancer cells and pharmaceut-
ical approaches targeting cell metabolism hold potential
for treating cancer [1]. Nicotinamide adenine dinucleotide
(NAD+) plays a key role in different biochemical processes,
acting as a coenzyme in redox reactions or as a substrate
for NAD+ degrading enzymes, such as poly(ADP-ribose)
polymerases (PARPs), cluster of differentiation 38
(CD38), and sirtuins. Intracellular NAD+ is continuously
replenished utilizing either tryptophan, nicotinamide, nico-
tinic acid or nicotinamide riboside as a substrate [2], and
nicotinamide phosphoribosyltransferase, NAMPT, is the
rate-limiting enzyme for NAD+ biosynthesis from nicotina-
mide in mammalian cells [3]. High NAMPT levels, whose
activity appears to be also important in the differentiation
of myeloid cells [4], were shown to be required to support
cancer cell growth, survival and epithelial-mesenchymal
transition (EMT) transition [5, 6], and have been reported
in different types of tumors [7, 8]. In line with these no-
tions, several studies have highlighted a strong activity of
NAMPT inhibitors in preclinical models of inflammatory
and malignant disorders, including leukemia [2, 9–11].
FK866, a prototypical NAMPT inhibitor, was found to
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promote cell death in both lymphoid- and myeloid-derived
hematological malignancies and its activity clearly resulted
from intracellular NAD+ depletion [12–14]. Notably,
opposite to cancer cells, activated immune cells [10], along
with many other types of healthy cells, such as
hematopoietic stem cells [12], appear unaffected by
NAMPT inhibitors, and consistently, agents such as FK866
or CHS-828 are well tolerated in patients [15, 16].
The molecular consequences upon NAMPT inhibition
are only partially understood. The induced NAD+ deple-
tion clearly affects intracellular ATP levels resulting in
mitochondrial dysfunction and activation of cell death
pathways: reactive oxygen species generation and activa-
tion of the apoptotic cascade have both been involved in
cell demise in response to NAMPT inhibitors [17]. ATP
depletion has been related to the loss of plasma mem-
brane homeostasis invariably leading to oncosis cell death
[18]. Different groups have suggested a role for autophagic
cell death in the cytotoxic activity of these drugs [10, 12,
13, 19]. In particular, Cea and colleagues proposed that
FK866 would induce autophagy via activation of
transcription factor EB (TFEB), a master regulator of
the lysosomal-autophagic pathway [20], and through
MTORC1/AKT and ERK1/2 pathway inhibition [21].
There is also evidence that AMP-activated protein kinase
(AMPK), an important coordinator of metabolic pathways
in response to energetic fluctuations [22], is activated by
FK866 in prostate cancer cells affecting lipogenesis [23]
and in hepatocarcinoma cells with impact on MTOR/
4EBP1 signaling [24]. Moreover, NAMPT-dependent
AMPK activation associated with deacetylation of liver
kinase B1 (LKB1), an upstream kinase of AMPK, has been
linked with modulation of NAD levels and with significant
impact on neuron cell survival [25]. Translation inhibition
is often observed during cell stress [26] and this event
often involves a re-programming of translation leading to
differential regulation of mRNAs, occurring also via alter-
native mechanisms, aimed at reorganizing cell physiology
to respond to the insult.
In this study, we focused on the pre-toxic molecular
events induced by FK866 in acute lymphoblastic leukemia
cells, known to be sensitive to the drug [10], in order to
define the molecular mechanism favoring cell death or cell
survival. A marked global protein synthesis inhibition rep-
resented an early cellular response associated with the
FK866-induced energetic stress and here we show that
AMPK-EIF2A is a central hub in mediating this effect and
is responsible for cell fate decisions.
Methods
Cell lines, primary B-CLL cell and T-ALL PDX isolation
Human Jurkat T-cell acute lymphoblastic leukemia (T-
ALL) cells were purchased from the InterLab Cell Line
Collection bank (ICLC HTL01002). SUP-T1 cells were
purchased from ATCC (CRL-1942) and Molt-4 Clone 8
from NIH AIDS Reagent Program (Catalog #: 175).
Human lung carcinoma A594 (CCL-185) and H460
(HTB-177) cells were purchased from ATCC. These cells
were transduced with retroviral vectors encoding either
LKB1 cDNA (pBABE-LKB1) or the pBABE control vec-
tor. Cell lines were grown in complete RPMI 1640
(Gibco Life Technologies) supplemented with 10 % fetal
bovine serum (FBS, Lonza), 2 mM L-glutamine, 100 U/
ml penicillin-streptomycin (Lonza). All cell lines were
grown at 37 °C under 5 % CO2 and regularly tested for
mycoplasma contamination. For primary B-CLL cell iso-
lation, a 5 ml blood sample was obtained from patients
presenting with marked lymphocytosis (>20000/μl) ac-
cording to a protocol that was approved by the Ethics
Committee of the Hospital IRCCS AOU San Martino
IST in Genoa (#840, February 18th 2011). Patients’ writ-
ten informed consent was collected. B-CLL cells were
isolated by density gradient centrifugation on Ficoll-
Hypaque (Biotest). The phenotype of the obtained cell
preparations was confirmed by immunostaining with
anti-CD19, anti-CD5, and anti-CD23 (Immunotech), and
subsequent flow cytometric analysis. T-ALL xenografts
(PD T-ALL) were established from BM (bone marrow) of
newly diagnosed ALL pediatric patients, according to a
protocol approved by the ethics committee of the Univer-
sity of Padova (Project number 16B/2013). The PD T-ALL
cells used in this study have been published elsewhere
[27]. At time of PD T-ALL establishment, written in-
formed consent was obtained from the parents of the chil-
dren. In vitro studies were performed with T-ALL cultures
established from the spleen of the xenografts. Purity of the
cultures (in terms of percentage of human CD5+ cells)
was checked by flow cytometry and was always >85 %. Re-
search carried out on human material was in compliance
with the Helsinki Declaration.
Chemicals
FK866 (sc-205325) was bought from Santa Cruz, Com-
pound C (P5499), Nicotinic acid (N0761), Actinomycin
D (A9415), (S)-(+)-Camptothecin (C9911), Cyclohexi-
mide (C1988), MG-132 (M7449), Doxorubicin hydro-
chloride (D1515) and Dexamethasone (D4902) were
bought from Sigma-Aldrich, CHS-828 (200484-11-3)
from Cayman chemical, Torin 1 (S2827) and Rapamycin
(S1039) from Selleck Chemicals, Cisplatin (ALX-400-
040) from Enzo Life Sciences and Propidium Iodide
Staining Solution from BD Pharmingen. Jurkat cells were
treated with drugs dissolved in DMSO at the same cell
density (5X105 cells/ml).
Viability assays
Cell viability was assessed with the Annexin V-FITC
Apoptosis Detection Kit I and 7-Aminoactinomycin D
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(7-AAD) Staining Solution (BD Pharmingen) according
to manufacturer’s instruction. EC50 values of FK866 were
determined by nonlinear regression analysis (GraphPad
Prism software v5.01,) vs viable cells in mock conditions
(DMSO).
Jurkat, A549 and H460 cell lines were grown and
treated in 96 well-plate for 48 h. Cells were then assayed
for viability using Thiazolyl blue tetrazolium bromide
(MTT) M5655 (Sigma). In brief, MTT (5 mg/ml) at
10 % volume of culture media was added to each well
and cells were further incubated for 2 h at 37 °C. Then
100 μl of DMSO was used to dissolve formazan. Absorb-
ance was then determined at 565 nm by microplate
reader. Cell survival was calculated and EC50 values were
determined.
Determination of NAD+-NADH and ATP levels and
caspase/protease activity
Intracellular NAD+-NADH content was assessed with a
NAD+-NADH Quantification Kit (BioVision) according to
the manufacturer’s protocol. Intracellular ATP content
was determined using Cell titer Glo Luminescent Cell Via-
bility Assay (Promega). NAD+-NADH and ATP values
were normalized to the number of viable cells as deter-
mined using Trypan Blue (Lonza). EnzChek Protease
Assay Kit, containing a casein derivative labeled with
green-fluorescent BODIPY FL (Life Technologies), was
used to determine protease activity after treatment of
2x106 cells. Cells were washed once with PBS and lysed in
500 μl of 1X digestion buffer, sonicated and centrifuged
for 5 min at maximum speed. One μl of the BODIPY ca-
sein 100X was added to 100 μl of the supernatant and in-
cubated for 1 h protected from light. Fluorescence was
measured and normalized to protein concentration in the
cell lysates (Bradford Reagent, Sigma). Caspase-Glo 3/7
Assay (Promega) was used to quantify caspase activity.
RNA and protein click-iT labeling kits
Click-iT RNA Alexa Fluor 488 Imaging Kit (Life Tech-
nologies) was used to quantify the level of global RNA
synthesis by flow-cytometry. Jurkat cells (3x106/sample)
were treated for 45 h with FK866 (or DMSO) and then
incubated for 3 h with 1X EU working solution without
removing the drug-containing media. EU detection was
performed following the manufacturer’s protocol after
cell fixation and permeabilization. Click-iT AHA Alexa
Fluor 488 Protein Synthesis Assay (Life Technologies)
was used to measure the rate of translation. Cells
(3x106/sample) were treated for 45 h with FK866, centri-
fuged and incubated for 3 h with 50 μM AHA in L-
methionine-free medium (RPMI Medium 1640,
Sigma-Aldrich) containing the drug (or DMSO). After
fixation and permeabilization, AHA incorporation was
assessed by flow cytometry. 7-AAD Staining Solution
(0.25 μg/sample) allowed the exclusion of non-viable cells.
Western blotting, antibody list and plasmids
Cells were lysed for 5 min on ice in RIPA lysis buffer
supplemented with Protease Inhibitor Cocktail (Sigma-
Aldrich). After sonication and clarification, equal amounts
of proteins were separated by SDS–PAGE and blotted
onto PVDF membranes (Immobilon-P, Millipore), as in
[28]. The antibodies used were: 4EBP1 (sc-6936), p-4EBP1
(Ser 65/Thr 70; sc-12884), EIF4E (sc-9976), p-EIF4E (Ser
209; sc-12885), AKT1/2/3 (sc-8312), p-AKT1/2/3 (Ser
473; sc-7985), MTOR (sc-8319), BCL-2 (sc-509), NAMPT
(sc-130058) from Santa Cruz; EIF2S1 (ab26197), p-EIF2S1
(Ser 51; ab32157), and p-MTOR (Ser 2448; ab1093) from
Abcam; AMPKα (2603), p-AMPKα (Thr 172; 2531), ACC
(3676) and p-ACC (Ser 79; 3661) and MCL1 (4572) from
Cell Signaling. A mouse anti-β-actin antibody (3700, Cell
Signaling) was used as a protein loading control. eIF2a 1
(Addgene plasmid # 21807), eIF2a 2 (Addgene plasmid #
21808) and eIF2a 3 (Addgene plasmid # 21809) were a gift
from David Ron. A549 cells were transfected using Lipo-
fectamine 3000 Reagent from Life Technologies. Cells
were plated in 6 well and transfected at 70 % confluence
for 24 h with 1 μg of DNA. Jurkat cells were transfected
for 48 h with 1 μg of DNA in 24- well plate.
Real-time PCR
Total RNA was extracted with Quick-RNA MiniPrep kit
(Zymo Research) and treated with DNAse. cDNA was
synthesized using RevertAid First Strand cDNA Synthe-
sis Kit (Fermentas) following the manufacturer’s recom-
mendation. Real-time PCR reactions were performed
using the KAPA SYBR FAST Universal qPCR Kit on a
CFX96 Real-Time PCR Detection System (BioRad). Rela-
tive mRNA quantification was obtained with the ΔCq
method using β-actin (ACTB) as housekeeping gene.
Primers’ sequences are reported as follows: BiP/Grp78
(Fw: TGTTCAACCAATTATCAGCAAACTC Rev: TTC
TGCTGTATCCTCTTCACCAGT) ACTB (Fw: CTGGA
ACGGTGAAGGTGACA Rev: AGGGACTTCCTGTAA
CAATGCA) STK11/LKB1 (Fw: GAGCTGATGTCGGT
GGGTATG Rev: CACCTTGCCGTAAGAGCCT).
Lentiviral particles production and luciferase assay
Lentiviral particles were produced using the pHR-SIN-R-
Myc-F, pHR-SIN-F-HCV-R and pHR-SIN-F-CrPV-R
transfer vectors [29], coding for reporter genes controlled
by a cMyc-5′UTR, HCV or CrPV IRESes regulated trans-
lation, by co-transfection of 293 T cells with the packaging
plasmid pCMV-deltaR8.91 and the VSV envelope-coding
plasmid pMD2.G. Five thousand Jurkat cells/sample were
transduced. After treatment with FK866, luciferase activity
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was measured using the Dual-Glo Luciferase Assay Sys-
tem (Promega) and normalized for protein concentration.
Silencing with shRNAs
The pLKO.1-based lentiviral plasmids containing AMPKa1
shRNA (TRCN0000000859), AMPKa2 shRNA (TRCN0000
002169) or NAMPT shRNA expression cassette (TRCN
0000116180) and (TRCN0000116181) were purchased
from Sigma-Aldrich. Scramble shRNA (Addgene plas-
mid #1864 [30]) was used as a control. Vectors were
produced in 293 T cells by cotransfection of the dif-
ferent transfer vectors with the packaging plasmid
pCMV-deltaR8.91 and the VSV envelope-coding plas-
mid pMD2.G. 1 million of Jurkat cells were trans-
duced with lentiviral particles expressing the control
(shSCR) or NAMPT-silencing short hairpin RNA
(shNAMPT) by spinning them down with vector-con-
taining supernatants for 2 h at 1600xg at room
temperature and leaving them incubate overnight at 37 °C
without replacing the transduction supernatant. After
changing the medium, the cells were further incubated for
72 h before collection for WB.
For AMPK silencing experiments, Jurkat cells were
first transduced with the shRNA vector targeting the α1
subunit (shAMPKα1) as reported before. After 24 h
from the first transduction the cells were then trans-
duced again, following the same protocol, with the lenti-
viral vector coding for the shRNA targeting the AMPK
α2 subunit (shAMPKα2). After changing the medium
the next morning, the cells were further incubated for
48 h and then treated for additional 48 h with or without
(DMSO) 5 nM of FK866.
To obtain LKB1 silencing, pLKO.1 transfer vectors
were prepared by cloning annealed oligos coding for
shRNAs (clone TRCN0000000408 for LKB1-A and clone
TRCN0000000409 for LKB1-B) into the TRC cloning
vector (Addgene plasmid #10878 [31] according to the
TRC standard protocol. Cells were transduced by spin-
ning them down with vector-containing supernatants
and leaving them incubate overnight. After changing the
medium, the cells were incubated for 72 h and then
treated for additional 48 h with or without FK866.
Statistical analysis
Experiments were performed in biological triplicates. T-
test was used to calculate final p-values, without assum-
ing variances to be equal (Welch’s t-test). P-value <0.05
was considered statistically significant.
Results
Sensitivity of leukemia cells to the NAMPT inhibitor
FK866
FK866 was previously shown to have cytotoxic activity
at nanomolar concentrations against different types of
hematological malignancies, including myeloid and
lymphoid leukemias and multiple myeloma [12, 21]. We
monitored FK866-induced cell death in Jurkat cells by
quantifying early and late apoptosis with 7AAD and
Annexin V staining. In line with previous reports, FK866
cytotoxic activity started to become evident between 48
and 72 h of exposure with approximately 74 and 47 % of
viable cells left at these time points when cells are
treated with FK866 100 nM (Fig. 1a), respectively. This
suggests the existence of a lag phase through which cells
can cope with the energetic shortage. Starting from a
concentration of 10 nM, FK866 cytotoxic activity
reached a plateau and an EC50 of 5.3 nM could be esti-
mated after 48 h of exposure (Fig. 1a). Indeed, at 120 h
we measured an effective IC50 of 10 nM, highlighting
the inability of these cells to compensate for the ener-
getic stress induced by FK866 in long term treatment
(Fig. 1a). Cell cycle analysis of FK866-treated cells, at
48 h, showed a non-significant accumulation of cells in
G2/M phase, while, as predicted, serum starvation re-
sulted in accumulation of cells in G0/G1 phase (Fig. 1b
and Additional file 1A). Forty-eight hours treatment
with FK866 led to approximately 25 % of cell death, but
did not lead to massive protease or caspase activation
(Fig. 1c and d). However, 5 nM FK866 was sufficient to
effectively reduce NAD+(H) and ATP levels in Jurkat
cells, representing a pre-toxic experimental condition to
apply for further experiments (Fig. 1e).
FK866 and NAMPT ablation blocks cap-dependent
translation, but not gene transcription, through MTOR/
4EBP1, EIF4E, and EIF2A inhibition in cancer cells
We assessed the impact of FK866 on global transcrip-
tional and translational efficiencies in Jurkat cells. Global
RNA transcription and translation were monitored using
the Click-it chemistry and flow-cytometry by the incorp-
oration of the nucleoside analog 5‑ethynyl uridine (EU)
and of an aminoacid analog (AHA), respectively. In the
viable Jurkat cell population, FK866 caused a reduction
in the incorporation of EU in a dose–dependent manner,
with 70 and 55 % of transcriptionally active cells in the
presence of 5 and 100 nM FK866, respectively. Thus,
despite NAD+ and ATP depletion, cells treated with
FK866 for 48 h essentially retained their ability to per-
form RNA transcription. By contrast, even 5 nM FK866
determined a striking reduction (up to 30 %) of the frac-
tion of viable cells showing active protein synthesis
(Fig. 2a and Additional file 1B). The utilization of bicis-
tronic reporter assays to test the efficacy of cap or IRES
(Internal Ribosome Entry Site) dependent translation
confirmed that FK866 induced a strong translation arrest
with a major impact on cap-dependent translation in
Jurkat cells (Additional file 2).
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Since the initiation phase is considered the limiting
step of translation [32], we evaluated the activation of
three signaling pathways regulating the canonical cap-
dependent translation process. The Mammalian Target
of Rapamycin (MTOR) kinase regulates the p70 riboso-
mal S6 kinase (p70-S6K) and the eukaryotic translation
initiation factor 4E-binding protein 4EBP1, whose phos-
phorylation determines EIF4E availability for its interact-
ing partner EIF4G, which is involved in mRNA
recruitment to the ribosomes for protein translation
[32]. It has been recently shown that FK866 induces
MTOR de-phosphorylation [24], thereby inducing au-
tophagic cell death in multiple myeloma cells [21, 33].
As shown in Fig. 2b, Jurkat cells treated with FK866
indeed showed a marked de-phosphorylation of MTOR
and 4EBP1. Enhanced AKT phosphorylation at Ser-473
was also observed (Fig. 2b), which is in line with the
paradoxical activation of AKT by MTORC2 complex fol-
lowing inhibition of MTOR as reported with different
MTOR inhibitors in multiple myeloma cells [34]. Not-
ably, treatment with FK866 led to a previously unappre-
ciated de-phosphorylation of EIF4E on serine 209,
suggesting that the MAP Kinase Interacting Serine/
Threonine Kinase (MNK)-dependent pathway is also af-
fected [35] (Fig. 2c), and to an increased phosphorylation
on Ser-51 of EIF2A, an initiation factor that transfers
methionyl-initiator tRNA (Met) to the small ribosomal
subunit. When phosphorylated (Fig. 2c), EIF2A loses its
Fig. 1 FK866 affects NAD+(H) and ATP levels in Jurkat cells leading to cell death. a Flow-cytometric quantification of cell viability with AnnexinV
(FITC) and 7AAD (PerCP-Cy5-5-A) staining. Jurkat cells were treated with FK866 for 48,72 and 120 h. Mock, 5 nM FK866 and 100 nM FK866 (at 48
and 72 h) are shown as representative samples. Flow-cytometry experiments were carried out on two biological replicates and statistics were
based on the acquisition of 10000 events/sample. b Cell-cycle analysis with PI staining of the nuclei after 48 h of treatment. Overnight serum
starvation is shown as positive control of induced cell cycle synchronization in G0/G1 phase. Histograms quantify the cell cycle phase distribution.
Flow-cytometry experiments were carried out on two biological replicates and statistics were based on acquisition of 30000 events/sample. Cell
cycle phase analysis was done using ModFit LT 3.2 software and the Sync Wizard model. c Jurkat cells were treated with FK866 for 48 h. Alternatively,
cells were exposed to 5 μM of Camptothecin for 4 h as a positive control. Protease activity in cell extracts was assessed with a commercially available
kit and values were normalized to the protein concentration in the same extracts. d Caspase 3/7 activity was measured in Jurkat cells treated as in c. e
Jurkat cells were treated with FK866 for 48 h. Thereafter, intracellular NAD+(H) and ATP levels were evaluated in comparison with control Jurkat cells.
RLUs were normalized to number of viable cells. In c-e the means with SD of at least three independent experiments are shown. Statistical significance
was calculated with t-test (* and # indicates p-value <0.05)
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ability to exchange GDP and GTP, impairing the forma-
tion of a complex with the EIF2B subunit and thus pre-
venting translation initiation [36]. Analogously, SUP-T1
and Molt-4 Clone 8 T-ALL cell lines presented the same
FK866-induced inhibition of the activation of 4EBP1,
supporting the existence of a general mechanism under-
lying the FK866-induced translational arrest in leukemia
cells (Fig. 2d, e). These effects were also observed using
another inhibitor of NAMPT enzymatic activity, CHS-
828 (Additional file 3A), but not with other commonly
used chemotherapeutics as cisplatin, doxorubicin, dexa-
methasone and rapamycin, at equivalent pre-toxic doses.
Indeed, FK866 induced a stronger protein synthesis ar-
rest than the MTOR inhibitor rapamycin suggesting that
this event is a molecular hallmark of FK866. Addition-
ally, FK886 concomitantly induced EIF2A phosphoryl-
ation and 4EBP1 de-phosphorylation, uniquely among
all the other drugs, thus mechanistically supporting the
strong protein synthesis arrest. The other drugs tested
were ineffective (Additional file 3B, C, D). In conclusion,
these experiments show the modulation of several hubs
of the signaling apparatus controlling translation initi-
ation in response to FK866, providing a robust
explanation for the marked protein synthesis inhibition
observed after drug treatment.
FK866 induces AMPK and EIF2A phosphorylation in Jurkat
and primary leukemia cells
In view of the strong translation inhibition and consider-
ing its energy-sensing activity in controlling translation
[37], we investigated in Jurkat cells the impact of FK866
and CHS-828 on the phosphorylation status of AMPK,
whose activation has been previously shown to be induced
by FK866 in prostate and hepatic cancer cells [23, 24].
FK866 caused a partial reduction in total AMPK levels at
the highest dose used, but, at a same time, a parallel dose-
dependent increase of the phosphorylation of its Thr-172
and of its bona fide target ACC (Acetyl-CoA Carboxylase)
(Fig. 3a), indicating a significant activation of AMPK. We
evaluated the effect of FK866 on two important antiapop-
totic factors, MCL1 (Myeloid Cell Leukemia 1) and BCL-2
(B-Cell Lymphoma 2). BCL-2 protein levels were essen-
tially not affected by FK866 treatment as compared to the
strong down-regulation of MCL1 (Fig. 3a). Notably, nico-
tinic acid (NA) supplementation, which blocks FK866
cytotoxic activity by allowing NAD+ biosynthesis through
Fig. 2 FK866 inhibits the signaling cascades controlling protein synthesis in T-ALL cell lines. a RNA synthesis was determined by monitoring EU
incorporation with Click-it chemistry. Jurkat cells were treated for 48 h with or without (Mock) the indicated concentration of FK866 or for 3 h with
5 μM Actinomycin D, an RNA synthesis blocking agent. The histogram quantifies the dose-dependent transcription inhibition induced by FK866
in the viable cell population. In the lower part, Click-it chemistry based on the incorporation of an aminoacid analog (AHA) was used to monitor
protein synthesis. Jurkat cells were treated for 48 h with or without (Mock) the indicated concentration of FK866 or for 3 h with 350 μM Cycloheximide,
as a positive control for protein synthesis inhibition. The histogram quantifies FK866-induced protein synthesis arrest in the viable cell population.
Flow-cytometry experiments were carried out on two biological replicates and statistics were based on acquisition of 50000 events/sample. b Jurkat cells
were treated for 48 h with or without (Mock) the indicated concentration of FK866. Thereafter, cells were lysed and the levels of total and p-Akt (Ser-473),
total and p-MTOR (Ser-2448), total and p-4EBP1 (Ser-65 and Thr-70), c) total and p-EIF4E (Ser-209), total and p-EIF2A (Ser-51) were detected by
immunoblotting. d Molt-4 cells were treated with FK866 for 48 h and the levels of total 4EBP1 and p-4EBP1 were evaluated. e Western blot analysis as
in d in SupT1 cells. b-e, one representative experiment out of at least three biological replicates is presented and β-actin was used as loading control
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an alternative pathway (via nicotinic acid phosphoribosyl-
transferase, NAPRT1), completely prevented AMPK phos-
phorylation in primary B-CLL (Fig. 3b, Additional file 3E),
confirming that NAD+ depletion is responsible for AMPK
activation. In patient-derived T-ALL xenografts (PD T-
ALL) the drug induced cell death and activated AMPK as
well as EIF2A phosphorylation (Fig. 3c and d), demon-
strating that this molecular event is not limited to cell line
models but is also present in primary leukemia cells.
EIF2A phosphorylation precedes 4EBP1 de-
phosphorylation in Jurkat cells
NAMPT expression level during FK866 treatment
remained unchanged as expected (Fig. 4a). Genetic abla-
tion of NAMPT by lentiviral transduction in Jurkat cells
(Fig. 4b) lowered NAD+(H) level to 75 % of the control
while ATP level was not significantly decreased thus in-
ducing an intermediate condition of energetic stress
compared to the one obtained with 5 nM FK866
administration (Fig. 4c). In these conditions of mild
stress, AMPK was marginally activated but, nevertheless,
we observed a significant phosphorylation of EIF2A but
not the de-phosphorylation of 4EBP1, suggesting that
the first event precedes the second one (Fig. 4d). Import-
antly, we observed a clear down-regulation of MCL1, as
observed with FK866 treatment (Fig. 3a), suggesting that
EIF2A activation is an early response to NAD+(H)
shortage.
FK866-induced AMPK activation regulates EIF2A
phosphorylation
To formally assess the role of AMPK in FK866-induced
translational arrest, we pharmacologically blocked
AMPK with Compound C, a small molecule inhibitor of
this enzyme, although not selective [38]. In addition, we
down-regulated AMPK using lentiviral transduction of
shRNAs. Compound C administration to Jurkat cells
treated with FK866 abrogated AMPK phosphorylation,
Fig. 3 FK866 induces AMPK and EIF2A phosphorylation in primary leukemia cells. a Jurkat cells were treated for 48 h with or without (Mock) the
indicated concentration of FK866. Thereafter, cells were lysed and the levels of total and p-AMPK (Thr-172), ACC and p-ACC, BCL-2, MCL1 and
β-actin as loading control were detected by immunoblotting. One representative experiment out of three biological replicates. b primary B-CLL
cells (source: peripheral blood; RAI stage III, 86 years, CD38-pos) were treated for 48 h with or without FK866 in the presence or absence of 1 mM
NA. Thereafter, protein lysates were immunoblotted for AMPK and p-AMPK. c Cell viability with respect to Mock condition, measured by CellTiter
Glo, of three different T-ALL xenografts (PD T-ALL 12, 19 and 25) after treatment with FK866 5nM for 48 h. d WB of PD T-ALL 12 as representative
of T-ALL xenografts samples. Cells were treated with 5 and 50 nM FK866 for 48 h. Histogram shows the densitometric analysis of p-AMPK and
p-EIF2A in the three T-ALL xenografts (PD T-ALL 12, 19 and 25)
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reactivated the MTOR/4EBP1 pathway and restored
EIF2A in its un-phosphorylated state (Fig. 5a). Rescue
experiments with Compound C did not show any down-
regulation of MCL1 protein level with no change in
BCL2 expression (Fig. 5a). Co-treatment with Com-
pound C partially reverted FK866-induced ATP loss but
activated the apoptotic response (Fig. 5b). Down-
regulation of AMPK was achieved by targeting both
AMPKα1 and AMPKα2 isoforms (shAMPK cells). We
then exposed silenced and control (scramble) cells to 5
nM of FK866 for 48 h (Fig. 5c). In shAMPK cells we ob-
served a significant decrease of EIF2A phosphorylation
but not of 4EBP1 de-phosphorylation. This supports the
notion that FK866-induced AMPK activation is primar-
ily involved in the regulation of EIF2A phosphorylation
and subsequently in 4EBP1 de-phosphorylation (Fig. 5c).
Importantly, shAMPK Jurkat cells showed an increased
sensitivity to FK866 with respect to control cells, as re-
vealed by PI staining and flow-cytometry (Fig. 5d),
pointing out the protective effect of AMPK in FK866-
induced stress conditions.
EIF2A mediates the AMPK pro-survival effect during
FK866 treatment
Given the protective role of AMPK in a context of
FK866-sensitive cancer cell, we hypothesized that the
liver kinase B1 (LKB1), a well-established AMPK regula-
tor, can also exert the same protective effect. Indeed,
genetic ablation of LKB1 in Jurkat cells led to an in-
crease toxicity of FK866 treatment (Fig. 6a). Accordingly,
we used two lung adenocarcinoma cell lines (H460 and
A549), bearing genetic inactivation of LKB1 to prove the
dependency of FK866 efficacy on the activation of the
LKB1/AMPK pathway. These results provide a rationale
for the utilization of NAMPT inhibitors in cancers with
this type of genetic background. The cells were stably
transduced with retroviral vectors encoding parental
LKB1 cDNA (LKB1 WT) or with a control vector
Fig. 4 NAMPT genetic ablation induces EIF2A phosphorylation and MCL1 down-regulation. a Expression levels of NAMPT. Jurkat cells were treated
with 5 and 100 nM FK866 for 48 h. One representative experiment out of three biological replicates is presented. b WB analysis indicated 50 % of
NAMPT silencing (p < 0.001) in Jurkat cells by using lentiviral particles expressing two NAMPT-silencing shRNAs (shNAMPT-1 and −2). c Intracellular
NAD+(H) and ATP levels in shNAMPT cells (transduced with shNAMPT-1 and −2) were evaluated in comparison with scramble Jurkat cells. Thirty
percent reduction of NAD+(H) levels was observed in shNAMPT cells (p-value < 0.01). RLUs were normalized to number of viable cells. Mean and SD of
a biological triplicate. d WB analysis of AMPK, p-AMPK, EIF2A, p-EIF2A, p-4EBP1 and MCL1 in shNAMPT (transduced with shNAMPT-1 and −2) cells.
Histogram shows the densitometric analysis of p-AMPK, p-EIF2A and MCL1 (* indicates p-value <0.05). Mean and SD of a biological triplicate
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Fig. 5 AMPK regulates EIF2A phosphorylation and is a pro-survival factor in Jurkat cells. a Jurkat cells were treated with or without FK866 at the
indicated concentrations in the presence or absence of Compound C 5 μM for 48 h. Thereafter, cells were lysed and the levels of p-AMPK (Thr-172),
p-MTOR, 4EBP1, p-4EBP1, BCL-2, MCL1, EIF2A and p-EIF2A were revealed by immunoblotting. Histogram shows the densitometric analysis of p-AMPK
and p-EIF2A. b In the same samples, caspase 3/7 activity was quantified and relative ATP levels were determined and then normalized to the number
of viable cells (* indicates p-value <0.05). a and b are representative of a biological triplicate (mean and SD). c Jurkat cells were transduced with
lentiviral particles containing scramble or shAMPK (targeting the α1 and the α2 subunit), then treated for 48 h with or without 5 nM FK866. Cell lysates
were used for total AMPK, EIF2A, p-EIF2A, 4EBP1, p-4EBP1 and β-actin immunoblotting. WB analysis indicated 40 % of AMPK silencing (p-value < 0.05)
and densitometric analysis shows the significant decrease of p-EIF2A in shAMPK Jurkat cells (p-value < 0.03). Mean and SD of a biological triplicate. d
Jurkat scramble and shAMPK cells were treated for 48 h with the indicated doses of FK866. Cell viability was determined by PI staining and flow-
cytometry (two biological replicates and statistics based on the acquisition of 10000 events/sample)
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(pBABE). FK866 treatment induced AMPK and EIF2A
phosphorylation in addition to 4EBP1 de-phosphorylation
only when LKB1 was active. On the other hand, albeit to a
different extent among the two cell lines, FK866 was not
able to activate AMPK or EIF2A but was still effective in
de-phosphorylating 4EBP1 when LKB1 was inactive. Via-
bility assays indicated an increased sensitivity of LKB1
negative, EIF2A un-phosphorylated cells to FK866 com-
pared to LKB1 expressing cells (Fig. 6b and Additional file
4A). Finally, in order to assess the relevance of EIF2A in
mediating the AMPK induced protection from FK866, we
treated with the drug A549 and Jurkat cells transfected
with EIF2A, its phosphomimetic mutant S51D or with the
non-phosphorylatable mutant S51A. In the context of in-
active LKB1, the overexpression of EIF2A and the EIF2A-
S51D isoform led to a protective effect, while the alanine
mutant induced an increase of cell toxicity (Fig. 6c). The
same trend was observed also in Jurkat cells (Additional
file 4B). Therefore, these data indicate that the translation
arrest induced by EIF2A mediates the protective effect of
AMPK from FK866 induced stress.
EIF2A balances pro-survival and pro-death pathways
EIF2A is a key factor regulating the translation machin-
ery in response to a myriad of factors including nutrient
depletion, presence of exogenous mRNA and the Un-
folded Protein Response (UPR) following the induction
of Endoplasmic Reticulum (ER) stress [39]. Indeed,
FK866 induced the overexpression of BiP/Grp78 mRNA,
coding for a chaperone involved in the folding of ER
proteins (Fig. 6d), thus indicating UPR activation in
Jurkat cells after 48 h treatment. Moreover, FK866 in-
duced MCL1 down-regulation was dependent on prote-
asome activation as demonstrated by the rescue of its
expression level by MG132 treatment in Jurkat cells
(Fig. 6e) [40]. In conclusion, FK866 induces an AMPK-
Fig. 6 Protective role of EIF2A and FK866 induced UPR. a Expression level of LKB1 mRNA, evaluated in Jurkat cells after 120 h of lentiviral
transduction with shRNAs expressing the control sequence (scramble) or two LKB1-silencing shRNAs (shLKB1-a and –b), in the upper panel. Cells
were transduced for 72 h and then treated with FK866 for 48 h. Viability was measured by MTT assay in comparison with Mock (DMSO) condition,
in the lower panel. Mean and SD of a biological triplicate (*, p-value < 0.05). b WB analysis indicated the levels of AMPK, p-AMPK, p-EIF2A, p-4EBP1
in A594 cells expressing LKB1 (LKB1 WT) or transduced with an empty vector (pBABE) treated or not (Mock) with 100 nM FK866 for 48 h, left
panel. A549 cells were treated with indicated concentration of FK866 for 48 h and cell viability as shown in dose–response curve was evaluated
by MTT assay, right panel. Mean and SD of three biological replicates. c A549 viability after 48 h of treatment with FK866 100 nM in un-transfected
(NTC) cells and transfected with EIF2A wild type, EIF2A-S51A, EIF2A-S51D (mean and SD of three experiments,*, p-value < 0.05). d Expression level of
BiP mRNA, evaluated in Jurkat cells after 48 h of treatment with FK866 5nM (*, p-value < 0.0005). Mean and SD of a biological triplicate. e WB analysis
of MCL1 in Jurkat cells treated with FK866 for 48 h and with the proteasome inhibitor MG132 1 μM for 24 h. MG132 was added after 24 h of FK866
treatment. One representative experiment out of three biological replicates
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EIF2A mediated translational arrest, which is responsible
for MCL1 down-regulation and the activation of the
UPR response, that is a strategic pausing step necessary
to protect cells from FK866-induced energetic stress.
Discussion
We investigated the link between NAD+(H) depletion
and cell death using a T-ALL cell model after induc-
tion of the primary effects of NAMPT inhibition,
namely NAD+(H) and ATP depletion, while nearly
preserving total cell viability. The functional conse-
quences of NAD+(H) depletion upon FK866 treatment
resulted in a marked inhibition of the three major
pathways regulating the translation process and in a
striking arrest of protein synthesis. Interestingly,
FK866 efficacy in blocking protein synthesis was
higher than all the other chemotherapeutics tested
and even higher than the MTOR inhibitor rapamycin,
suggesting that this is a crucial event in the cell re-
sponse to FK866. This phenomenon is general be-
cause it was observed in primary leukemic samples,
coming both from B-CLL and T-ALL patients, and in
T-ALL derived cancer cell lines. Nicotinic acid rescue
experiments, treatment with the FK866 analog CHS-
828 and NAMPT genetic ablation showed that trans-
lation arrest was dependent on the shortage of ATP
and NAD+(H) induced by the inhibition of the
NAMPT catalytic function and not by unspecific
FK866 effects. FK866 has been shown to have con-
trasting effects on AMPK. In neuronal cells FK866
decreased AMPK activation and was detrimental for
neuronal survival [25], however in cancer cells that
have a dysregulated metabolic demand, it has been
observed the opposite. In prostate cancer cells, FK866
treatment reduced fatty acid and phospholipid synthe-
sis, partly via AMPK activation [23]. FK866 induced
activation of AMPK and subsequent decreased phos-
phorylation of 4EBP1 by MTOR has been observed in
hepatocarcinoma cells. Given the importance of
MTOR in sustaining cancer cell growth, this event
was proposed as an effective mechanism to target
cancer cells [23]. By evaluating the early molecular effects
of FK866 treatment on protein synthesis, we observed the
involvement of the same pathway but, in addition, we
showed a protective role for AMPK and EIF2A. In our ex-
perimental conditions, the inactivation of MTOR by
AMPK and consequent protein synthesis arrest had a pro-
tective effect conferring temporary resistance to the
FK866-induced energetic stress. Additionally, we deter-
mined that AMPK-induced hyper-phosphorylation of
EIF2A is regulated by the fluctuations of NAD availability
at the intracellular level. This molecular mechanism, lead-
ing to inhibition of translation initiation, followed AMPK
activation. In fact, genetic AMPK down-regulation of both
isoforms of the α catalytic subunit rescued the FK866 in-
duced hyper-phosphorylation of EIF2A. As a further con-
firmation, the same results were obtained by AMPK
functional ablation using the inhibitor Compound C or by
inactivation of its upstream regulator LKB1. Indeed, res-
cue of 4EBP1 phosphorylation levels was observed only
after Compound C administration, suggesting that EIF2A
is a preferential target of the AMPK signaling cascade, at
least in the initial phase of cell response to FK866. Inter-
estingly, in our cell model and at the doses we used, we
did not observe Compound C-induced phosphorylation of
EIF2A as recently reported in different cancer cells [41].
Our cell model resembles the AICAR-induced AMPK ac-
tivation that leads to EIF2A phosphorylation in adipocytes,
an event shown to be crucial for AMPK-induced apoptosis
[42], and supports the idea that FK866 induced activation
of the AMPK-EIF2A axis can be a novel pathway to be in-
vestigated to elucidate the pharmacology of FK866.
Many types of cancer, as sporadic lung, cervical, and
endometrial cancers, carry LKB1 deficiency that can be
exploited with metabolic drugs since these cells are un-
able to appropriately respond to metabolic stress [43].
Given the protective role of LKB1/AMPK pathway
against FK866, our study suggests the utilization of
FK866 as a metabolism-based cancer therapeutic to se-
lectively target LKB1-deficient tumors. Indeed in cells
lacking a functional LKB1 pathway, metabolic stress has
been demonstrated to result in rapid apoptosis as the
cells are unable to sense energetic stresses and activate
mechanisms to restore energy homeostasis [44].
Previous studies have shown that inhibition of the
MTOR/4EBP1 pathway in leukemia cells leads to a re-
duction in the levels of the anti-apoptotic protein
MCL1, with important implications for chemosensitivity
[45]. Down-regulation of MCL1 through inhibition of
translation has been clearly associated with enhanced le-
thality in Jurkat cells [46]. Importantly, FK866 adminis-
tration led to smooth death [40] via EIF2A-dependent
MCL1 down-regulation consequent to translation arrest
and simultaneous proteasome activation. Indeed, MCL1
intracellular levels were shown to be strictly dependent
on the activation of EIF2A [47] and AMPK [48], and to
the subsequent translation arrest. This could provide a
molecular explanation for the anti-leukemic activity of
NAMPT inhibitors. Notably, the ectopic expression of
the non-phosphorylatable mutant EIF2A-S51A increased
FK866 toxicity. Therefore the activation of the AMPK-
EIF2A axis is essential for the tumor cell to adapt to the
shortage of NAD+(H). For example, the increased ex-
pression level of BiP mRNA is a specific adaptive re-
sponse observed in the integrated stress response (ISR)
and translational repression [49]. The exacerbation of
proteasome inhibition with bortezomib has been shown
to potentiate FK866 efficacy through the activation of
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the caspases’ cascade [40]. Here we show the relevance
of EIF2A activation in this mechanism. Additionally, the
synergistic effect of FK866 with cyclosporine in leukemia
cells has been ascribed to the activation of the UPR [50].
This suggests that the exacerbation of the UPR, which is
dependent on EIF2A, can be thought as a relevant strat-
egy to potentiate the effect of FK866 in conditions in
which activation of the EIF2A-dependent UPR is desir-
able, i.e., diabetes, atherosclerosis, or neurodegenerative
disorders [51]. Indeed, FK866 effects on translation re-
semble the ones induced by metformin, a well-known
AMPK activator with antidiabetic and antitumoral prop-
erties [52, 53]. Finally, de-phosphorylation of EIF4E,
never linked to NAMPT inhibitors or AMPK activation
before, completes the general picture of a global inhib-
ition of the translation process, even though the mech-
anism leading to upstream MNK activation has not been
investigated yet.
Conclusions
In conclusion, this work describes the activation of a
complex signaling network in which the AMPK-EIF2A
axis is responsible for the early cellular response to the
metabolic stress produced by FK866. In an experimental
condition in which catastrophic proteolytic cascades are
not yet started but the energetic demand is high, EIF2A
acts as an early master regulator of cell fate, blocking
anabolic processes and, at the same time, modulating
cell death and adaptive pathways. Therefore EIF2A-
dependent processes, such as protein synthesis and UPR,
acquire fundamental relevance in explaining the mech-
anism of action of NAMPT inhibitors.
Additional files
Additional file 1: Cell-cycle analysis and Click-iT detection of RNA
and Protein synthesis. A) Cell-cycle analysis with PI staining of the
nuclei after 48 h of treatment. Overnight serum starvation is shown as a
positive control of induced cell cycle synchronization in G0/G1 phase. Cell
phase analysis was done with ModFit LT 3.2 software by using the Sync
Wizard model (30000 cells/sample in biological duplicate). B) Jurkat cells
were treated for 48 h with or without (Mock) the indicated concentration
of FK866 or for 3 h with 5 μM Actinomycin D, an RNA synthesis blocking
agent, then subjected to Click-it biochemistry and flow-cytometry
analyses including 7-AAD to identify living cells. C) Jurkat cells were
treated for 48 h with or without (Mock) the indicated concentration of
FK866 or for 3 h with 350 μM Cycloheximide, as a positive control for
protein synthesis inhibition, then stained as in B. In B and C. Experiments
were carried out on two biological replicates (50000 events/sample).
(PDF 1562 kb)
Additional file 2: Luciferase assays. A) Light units, normalized to
protein concentration, of RLuc-cMyc 5′UTR IRES-FLuc reporter vector
transduced in Jurkat cells with lentiviral particles after 48 h of treatment
with or without (Mock) the indicated concentration of FK866. Two hour
treatment with 250 nM of Torin 1 served as a positive control for IRES-
dependent protein translation (p-value <0.05). B) Light units, normalized
to protein concentration, of FLuc-HCV-RLuc and FLuc-CrPV-RLuc reporter
vectors transduced in Jurkat cells with lentiviral particles. Cap-dependent
translation (FLuc) was strongly reduced with 5 nM and 100 nM FK866
(48 h) in comparison to Mock condition (p-value <0.0001). RLuc signal is
not shown because of its low level and its variability between technical
and biological replicates. Cells transduced with the pHR-SIN-F-HCV-R were
serum starved for 5 h as a positive control of IRES activation, as shown in
the graph (p-value <0.05). In A and B data are represented as mean and
SD of three independent experiments. (PDF 584 kb)
Additional file 3: Effects of CHS-828 and chemotherapeutics on
protein translation. A) Jurkat cells were treated for 48 h with or without
(Mock) the indicated concentration of CHS-828. Caspase 3/7 activity was
quantified (using 5 μM of Camptothecin for 4 h as a positive control of
apoptosis) and relative ATP levels were determined and then normalized
to the number of viable cells. The levels of total AMPK, p-AMPK, total
EIF2A and p-EIF2A, total 4EBP1, p-4EBP1 were evaluated by WB. Histogram
shows the densitometric analysis of p-AMPK and p-EIF2A (* indicates p-value
<0.05). Mean and SD of a biological triplicate. B) Jurkat cells were treated with
the indicated concentration of drugs for 48 h and cell viability was measured
by Cell Titer Glo. Data are represented as mean and SD of three independent
experiments. C) Click-it chemistry based on the incorporation of an aminoacid
analog (AHA) was used to monitor protein synthesis. Jurkat cells were treated
for 48 h with or without (Mock) the indicated concentration of FK866,
Rapamycin (RAPA), Doxorubicin (DOXO), Cisplatin (CIS) and Dexamethasone
(DEXA). The histogram quantifies the % of AHA positive cells (active protein-
synthesizing cells) in the viable cell population. Flow-cytometry experiments
were carried out on two biological replicates and statistics were based on
acquisition of 20000 events/sample. D) Jurkat cells were treated as in C and
the level of p-EIF2A and p-4EBP1 was evaluated. Histogram shows the
densitometric analysis of p-EIF2A (* indicates p-value <0.05). Mean and SD of
a biological triplicate. E) Primary B-CLL cells were treated for 48 h with or
without 30 nM FK866 in the presence or absence of 1 mM NA. Histogram
shows the densitometric analysis of p-AMPK/AMPK. (PDF 691 kb)
Additional file 4: Protective role of EIF2A. A) WB analysis indicated
the levels of AMPK, p-AMPK, p-EIF2A, p-4EBP1 in H460 cells expressing
LKB1 (LKB1 WT) or transduced with an empty vector (pBABE) treated or
not (Mock) with 100 nM FK866 for 48 h, left panel. H460 cells were
treated with indicated concentration of FK866 for 48 h and cell viability
as shown in dose–response curve was evaluated by MTT assay, right
panel. Mean and SD of three biological replicates. B) Jurkat viability after
48 h of treatment with FK866 5nM in un-transfected (NTC) cells and
transfected with EIF2A wild type, EIF2A-S51A, EIF2A-S51D (mean and SD
of three experiments,§, p-value < 0.1). (PDF 274 kb)
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